Dextromethorphan Hydrobromide
| (DEX-troe-meth-OR-fan HIGH-droe-BROE-mide) |
| Benylin Adult |
| Liquid |
| 15 mg/5 mL |
| Benylin DM |
| Syrup |
| 10 mg/5 mL |
| Benylin Pediatric |
| Liquid |
| 7.5 mg/5 mL |
| Children’s Hold |
| Lozenges |
| 5 mg |
| Creo-Terpin |
| Liquid |
| 10 mg/15 mL (3.33 mg/ 5 mL) |
| Delsym |
| Liquid, sustained-action |
| Dextromethorphan polistirex equivalent to 30 mg dextromethorphan HBr/5 mL. |
| Diabetes CF |
| Syrup |
| 10 mg/5 mL |
| Drixoral Cough Liquid Caps |
| Capsules |
| 30 mg |
| Hold DM |
| Lozenges |
| 5 mg |
| Pediatric Vicks 44d Dry Hacking Cough and Head Congestion |
| Syrup |
| 15 mg/15 mL (1 mg/mL |
| Pertussin CS |
| Liquid 3.5 mg/5 mL |
| Pertussin ES |
| Liquid |
| 15 mg/5 mL |
| Robitussin Cough Calmers |
| Lozenges |
| 5 mg |
| Robitussin Pediatric |
| Liquid |
| 7.5 mg/5 mL |
| Scot-Tussin DM Cough Chasers |
| Lozenges |
| 2.5 mg |
| Silphen DM |
| Syrup |
| 10 mg/5 mL |
| St. Joseph Cough Suppressant |
| Liquid |
| 7.5 mg/5 mL |
| Sucrets 4-hr Cough |
| Lozenges |
| 15 mg |
| Sucrets Cough Control |
| Lozenges |
| 5 mg |
| Suppress |
| Lozenges |
| 7.5 mg |
| Trocal |
| Lozenges |
| 7.5 mg |
| Vicks Dry Hacking Cough |
| Liquid |
| 15 mg/5 mL |
| Balminil DM, Balminil DM Children, Benylin DM, Benylin DM for Children, Delsym, Koffex DM, Koffex DM Children, Robitussin Pediatric, Triaminic DM |
| Class: Antitussive, Nonnarcotic |
Action Suppresses cough by central action on cough center in medulla.
Indications Management of nonproductive cough.
Contraindications Standard considerations.
Route/DosageGelcaps Adults and children (at least 12 yr): PO 30 mg q 6 to 8 hr (max, 120 mg/day).
Lozenges Adults and children (at least 12 yr) PO 5 to 15 mg q 1 to 4 hr (max, 120 mg/day).
Children (6 to under 12 yr): PO 5 to 10 mg q 1 to 4 hr (max, 60 mg/day).
Liquid and syrup Adults and children (at least 12 yr): PO 10 to 20 mg q 4 hr or 30 mg q 6 to 8 hr (max, 120 mg/day).
Children (6 to under 12 yr): PO 15 mg q 6 to 8 hr (max, 60 mg/day).
Children (2 to under 6 yr): PO 7.5 mg q 6 to 8 hr (max, 30 mg/day).
Extended-release suspension Adults and children (at least 12 yr): PO 60 mg q 12 hr (max, 120 mg/day).
Children (6 to under 12 yr): PO 30 mg q 12 hr (max, 60 mg/day).
Children (2 to under 6 yr): PO 15 mg q 12 hr (max, 30 mg/day).
InteractionsMAO Inhibitors: Hypotension, hyperpyrexia, nausea, myoclonic jerks, and coma may develop after coadministration.
Lab Test Interferences None well documented.
Adverse ReactionsNausea, drowsiness, dizziness.
PrecautionsPregnancy: Category C. Lactation: Undetermined. Chronic cough: Do not use for persistent or chronic cough (eg, smoking, asthma, emphysema) or when cough is accompanied by excessive secretions. People with high fever, rash, persistent headache, nausea, or vomiting should use only under medical supervision. Drug abuse and dependence: Anecdotal reports of abuse have increased. However, abuse and dependency potential is undetermined.
| PATIENT CARE CONSIDERATIONS |
|
Administration/Storage- Store liquids, lozenges, and syrups at room temperature and out of reach of children.
Assessment/Interventions- Obtain patient history, including drug history and any known allergies. Note any respiratory problems and smoking history.
- Assess type of cough (dry or productive), severity, and progression.
- Assess baseline vital signs including fever.
- Do not administer for persistent or chronic cough, longer than 7 days, or when cough is accompanied by excessive secretions.
- Monitor blood glucose levels in diabetic patients.
|
||||
Patient/Family Education- Alert patient that many products contain alcohol.
- Instruct patient to notify health care provider before taking medication with other prescriptions (eg, MAOIs).
- Inform diabetic patients that base may contain sucrose or other sugars.
- Encourage increased fluid intake to thin secretions.
- Teach patients how to cough and breathe deeply to maximize respiratory efforts.
- Explain to parents not to give lozenges to young children.
Popularity: 4% [?]